J. Mamputu

发表

Signaling pathways involved in human vascular smooth muscle cell proliferation and matrix metalloproteinase-2 expression induced by leptin: inhibitory effect of metformin.

N. Wiernsperger, Ling-Hao Li, J. Mamputu, 2005, Diabetes.

Metformin inhibits monocyte adhesion to endothelial cells and foam cell formation

N. Wiernsperger, J. Mamputu, G. Renier, 2003 .

Lipoprotein lipase enhances human monocyte adhesion to aortic endothelial cells.

A. Desfaits, J. Mamputu, G. Renier, 1997, Journal of lipid research.

Population pharmacokinetic and pharmacodynamic analysis of tesamorelin in HIV-infected patients and healthy subjects

F. Nekka, J. Mamputu, M. González-Sales, 2015, Journal of Pharmacokinetics and Pharmacodynamics.

Differentiation of human monocytes to monocyte-derived macrophages is associated with increased lipoprotein lipase-induced tumor necrosis factor-alpha expression and production: a process involving cell surface proteoglycans and protein kinase C.

J. Mamputu, G. Renier, Geneviève Renier, 1999, Arteriosclerosis, thrombosis, and vascular biology.

Monocyte adhesion in diabetic angiopathy: effects of free-radical scavenging.

A. Desfaits, O. Serri, J. Mamputu, 2003, Journal of diabetes and its complications.

Effects of tesamorelin on inflammatory markers in HIV patients with excess abdominal fat: relationship with visceral adipose reduction

D. Potvin, S. Grinspoon, T. Stanley, 2011, AIDS.

Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial

D. Clemmons, J. Mamputu, Sam S. Miller, 2017, PloS one.

The influences of hyperprolactinemia and obesity on cardiovascular risk markers: effects of cabergoline therapy

Ling-Hao Li, O. Serri, J. Mamputu, 2006, Clinical endocrinology.

Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data.

D. Potvin, S. Grinspoon, G. Moyle, 2010, The Journal of clinical endocrinology and metabolism.

Effects of Tesamorelin, a Growth Hormone–Releasing Factor, in HIV-Infected Patients With Abdominal Fat Accumulation: A Randomized Placebo-Controlled Trial With a Safety Extension

D. Potvin, S. Grinspoon, D. Berger, 2010, Journal of acquired immune deficiency syndromes.

Benefits of gliclazide in the atherosclerotic process: decrease in monocyte adhesion to endothelial cells.

O. Serri, J. Mamputu, G. Renier, 2003, Metabolism: clinical and experimental.

Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin.

S. Grinspoon, T. Stanley, J. Mamputu, 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Antiatherogenic properties of metformin: the experimental evidence.

J. Mamputu, G. Renier, N. Wiernsperger, 2003, Diabetes & metabolism.

Advanced glycation end products increase, through a protein kinase C-dependent pathway, vascular endothelial growth factor expression in retinal endothelial cells. Inhibitory effect of gliclazide.

J. Mamputu, G. Renier, 2002, Journal of diabetes and its complications.

Lack of concordance between plasma markers of cardiovascular risk and intima‐media thickness in patients with type 2 diabetes

A. Roussin, J. Buithieu, O. Serri, 2004, Diabetes, obesity & metabolism.

Advanced glycation end‐products increase monocyte adhesion to retinal endothelial cells through vascular endothelial growth factor‐induced ICAM‐1 expression: inhibitory effect of antioxidants

J. Mamputu, G. Renier, J C Mamputu, 2004, Journal of leukocyte biology.

Signalling pathways involved in retinal endothelial cell proliferation induced by advanced glycation end products: inhibitory effect of gliclazide

J. Mamputu, G. Renier, 2004, Diabetes, obesity & metabolism.

Beneficial effects of gliclazide modified release compared with glibenclamide on endothelial activation and low‐grade inflammation in patients with type 2 diabetes

A. Roussin, J. Buithieu, O. Serri, 2007, Diabetes, obesity & metabolism.

Tesamorelin improves fat quality independent of changes in fat quantity

A. Scherzinger, G. Yenokyan, T. Brown, 2021, AIDS.

Gliclazide inhibits differentiation-associated biologic events in human monocyte-derived macrophages.

Ling-Hao Li, J. Mamputu, G. Renier, 2006, Metabolism: clinical and experimental.

Impact of Tesamorelin, a Growth Hormone‐Releasing Factor (GRF) Analogue, on the Pharmacokinetics of Simvastatin and Ritonavir in Healthy Volunteers

D. Potvin, M. Ducharme, J. Mamputu, 2013, Clinical pharmacology in drug development.

Population pharmacokinetic and pharmacodynamic analysis of tesamorelin in HIV-infected patients and healthy subjects

F. Nekka, J. Mamputu, M. González-Sales, 2015, Journal of Pharmacokinetics and Pharmacodynamics.

Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation

D. Potvin, S. Grinspoon, D. Kotler, 2008, AIDS.

Visceral fat reduction with tesamorelin is associated with improved liver enzymes in HIV

S. Grinspoon, T. Stanley, J. Mamputu, 2017, AIDS.

Predictors of Treatment Response to Tesamorelin, a Growth Hormone-Releasing Factor Analog, in HIV-Infected Patients with Excess Abdominal Fat

B. Hayward, A. Mangili, J. Mamputu, 2015, PloS one.

Metformin inhibits monocyte adhesion to endothelial cells and foam cell formation

N. Wiernsperger, J. Mamputu, G. Renier, 2003 .

Proliferative Effect of Lipoprotein Lipase on Human Vascular Smooth Muscle Cells

J. Mamputu, G. Renier, L. Lévesque, 2000, Arteriosclerosis, thrombosis, and vascular biology.